Mary Kate Davis's questions to Arrowhead Pharmaceuticals Inc (ARWR) leadership • Q3 2025
Question
Mary Kate Davis, on for David Lebowitz, asked how plozasiran addresses the unmet clinical need in familial chylomicronemia syndrome (FCS) and what physician feedback has been ahead of the potential launch.
Answer
SVP Andy Davis explained that plozasiran meets a critical need by providing deep triglyceride reduction and being the only agent in a Phase 3 trial to show a statistically significant reduction in acute pancreatitis risk. He also noted the convenient quarterly dosing as a key benefit for patients.